Riskpilot← Back to searchSign inGet full accessBio Solutions Consulting Sweden AB
ABActiveOrg 5593190761Mårdgatan 20Market research and public opinion polling · NACE 7320Est. 20211 employees
Revenue 2025
SEK 6,4M
+77% vs 2024
EBITDA margin
44.0%
+63% vs 2024
Equity ratio
67.2%
Financial strength
Net profit 2025
SEK 2,5M
+78% vs 2024
| Revenue | SEK 6,4M | +77% |
| EBITDA | SEK 2,8M | +63% |
| Net profit | SEK 2,5M | +78% |
| Total assets | SEK 5,7M | +123% |
| Equity | SEK 3,9M | +109% |
| Employees | 1 | — |
Legal name
Bio Solutions Consulting Sweden AB
Org number
5593190761
Legal form
Aktiebolag
NACE code
7320 · Market research and public opinion polling
Founded
25 maj 2021
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva konsultverksamhet inom forskning av altzeimers och relaterade sjukdomar och föreläsning samt därmed förenlig verksamhet.
Address
Mårdgatan 20
Email
antoine.leuzy@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 274 | 1 349 | 3 644 | 6 438 |
| Staff expenses | — | −205 | −1 196 | −1 066 |
| EBITDA | 263 | 1 036 | 1 741 | 2 833 |
| Depreciation & amort. | — | — | — | — |
| EBIT | 263 | 1 036 | 1 741 | 2 833 |
| Net financials | −0 | 0 | −4 | 265 |
| Profit before tax | 263 | 776 | 1 737 | 3 098 |
| Tax | −54 | −161 | −361 | −643 |
| Net profit | 209 | 615 | 1 376 | 2 455 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 288 | 1 158 | 2 568 | 5 739 |
| Equity | 234 | 661 | 1 842 | 3 855 |
| Long-term debt | — | — | — | — |
| Short-term debt | 54 | 237 | 466 | 1 624 |
| Total debt | 54 | 237 | 466 | 1 624 |
EBITDA margin
44.0%
This company
15.8%
Market median
+178% vs market
20222025
Equity ratio
67.2%
This company
38.2%
Market median
+76% vs market
20222025
Return on equity
63.7%
This company
18.4%
Market median
+246% vs market
20222025
Net profit margin
38.1%
This company
8.1%
Market median
+370% vs market
20222025
Asset turnover
1.12×
This company
1.12×
Market median
+0% vs market
20222025
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-25 – 2022-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Audit | 2026 | |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bio Solutions Consulting Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alf Niclas Ljunggren-Weidmann | Audit | 0 companies |
| Kerstin Elisabeth Leuzy Heurling | Deputy Board Member | 0 companies |
| Antoine Nicolas Leuzy | Board of Directors | 0 companies |
| Kerstin Elisabeth Leuzy Heurling | Deputy Board Member | 0 companies |